期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 16, 期 11, 页码 27107-27132出版社
MDPI
DOI: 10.3390/ijms161126000
关键词
bladder cancer; Polycomb; EZH2; miRNA; lncRNA
资金
- MINECO (Ministry of Economy and Competitiveness) [SAF2012-34378]
- Comunidad Autonoma de Madrid [S2010/BMD-2470]
- AES (Accion Estrategica en Salud) [ISCIII-RETIC RD12/0036/0009]
- MMA (Mutua Madrilena) Foundation [AP99782012]
- European Community
Bladder Cancer (BC) represents a current clinical and social challenge. The recent studies aimed to describe the genomic landscape of BC have underscored the relevance of epigenetic alterations in the pathogenesis of these tumors. Among the epigenetic alterations, histone modifications occupied a central role not only in cancer, but also in normal organism homeostasis and development. EZH2 (Enhancer of Zeste Homolog 2) belongs to the Polycomb repressive complex 2 as its catalytic subunit, which through the trimethylation of H3 (Histone 3) on K27 (Lysine 27), produces gene silencing. EZH2 is frequently overexpressed in multiple tumor types, including BC, and plays multiple roles besides the well-recognized histone mark generation. In this review, we summarize the present knowledge on the oncogenic roles of EZH2 and its potential use as a therapeutic target, with special emphasis on BC pathogenesis and management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据